Macquarie Group LTD Clovis Oncology, Inc. Transaction History

Macquarie Group LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $11,253 - $52,871	-17,862 Reduced 6.66%	250,200 $450,000
Q3 2021 Nov 12, 2021	BUY	$4.06 - $5.8 $69,056 - $98,652	17,009 Added 6.78%	268,062 $1.2 Million
Q1 2021 May 14, 2021	SELL	$4.81 - $10.34 $1,948 - $4,187	-405 Reduced 0.16%	251,053 $1.76 Million
Q2 2020 Aug 11, 2020	BUY	$5.69 - $9.69 $860,658 - $1.47 Million	151,258 Added 150.96%	251,458 $1.7 Million
Q4 2018 Feb 15, 2019	SELL	$11.63 - $32.67 $9.05 Million - $25.4 Million	-778,330 Reduced 88.59%	100,200 $1.8 Million
Q3 2018 Nov 15, 2018	BUY	$29.37 - $49.48 $5.49 Million - $9.26 Million	187,071 Added 27.05%	878,530 $25.8 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $3.18 Million - $4.72 Million	75,589 Added 12.27%	691,459 $31.4 Million
Q1 2018 May 11, 2018	BUY	$50.12 - $67.72 $4.8 Million - $6.48 Million	95,699 Added 18.4%	615,870 $32.5 Million
Q4 2017 Feb 15, 2018	SELL	$57.69 - $84.58 $387,042 - $567,447	-6,709 Reduced 1.27%	520,171 $35.4 Million
Q3 2017 Nov 08, 2017	BUY	$67.17 - $84.81 $35.4 Million - $44.7 Million	526,880	526,880 $43.4 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.